Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to address the need for stringent regulation of therapeutic goods, ensuring their safety, quality, and efficacy. The Act provides the legal framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. This encompasses the approval process for therapeutic goods, manufacturing standards, advertising controls, and licensing requirements for manufacturers and suppliers. The Act also empowers the Therapeutic Goods Administration to take actions such as revoking manufacturing licenses when deemed necessary to protect public health. The policy objective of the Act is to safeguard public health by ensuring that therapeutic goods available in Australia are of acceptable quality and are safe for their intended use. On 5 February 2019, Elga Maro, acting as a delegate of the Secretary of the Department of Health and the Therapeutic Goods Administration, published the revocation of manufacturing licenses for therapeutic goods. This action was taken under section 41(1)(d) of the Therapeutic Goods Act 1989, following requests from the manufacturers themselves. The revoked licenses pertain to Air Liquide Australia Limited, located in the Northern Territory, and Slade Health Pty Ltd, situated in New South Wales. This revocation reflects the administration's commitment to maintaining high standards in the manufacturing of therapeutic goods, ensuring that only compliant entities are permitted to operate within the regulated framework.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, establishing a comprehensive framework that ensures the safety, quality, and efficacy of these products. The Act applies to all therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and vaccines. It is applicable to all persons and entities involved in the manufacture, importation, supply, and advertising of these goods, thereby covering a wide range of industries including pharmaceuticals, biotechnology, and medical device manufacturing. The Act's jurisdiction extends nationally, as it is a Commonwealth Act, and applies to all states and territories within Australia. Notably, the Act allows for the establishment of various types of licences and permits necessary for the lawful manufacture and supply of therapeutic goods, with specific provisions for the revocation of such authorisations under certain circumstances, as evidenced by the revocation of licences for Air Liquide Australia Limited and Slade Health Pty Ltd. The Act also delineates certain exclusions and exemptions, such as specific conditions under which certain goods may be exempt from licensing requirements. Additionally, the Act provides for the creation of subordinate legislation, which can extend or restrict its application by detailing specific operational standards, procedural requirements, and other regulatory measures. This flexibility allows the Therapeutic Goods Administration to adapt the regulatory framework in response to evolving industry practices and emerging health concerns.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") governs the regulation of therapeutic goods in Australia, ensuring that such goods are safe, of high quality, and effective. Section 41(1)(d) of the Act allows the Secretary to revoke a manufacturer's licence to manufacture therapeutic goods if certain conditions are met. This notification under section 41(1)(d) specifies the revocation of two licences: the first held by Air Liquide Australia Limited, Licence No. MI-2010-LI-04989-3, and the second by Slade Health Pty Ltd, Licence No. MI-2012-LI-02240-3. Both revocations were carried out at the request of the manufacturers themselves. These revocations impose specific obligations on the parties involved. The manufacturers, having requested the revocation of their licences, are now subject to the terms and conditions that accompany such a revocation. This means they can no longer legally manufacture therapeutic goods in Australia. Additionally, they must ensure compliance with any transitional provisions that might be in place to mitigate the impact of the revocation on their operations or the supply of therapeutic goods. Failure to comply with the Act's requirements or the terms of the licence can lead to significant legal consequences. Under the Act, breaches can result in both civil and criminal penalties. Civil penalties may include fines and other monetary sanctions, while criminal offences can lead to imprisonment, with the maximum penalties varying depending on the nature and severity of the breach. The Act provides a robust framework to ensure that any breaches are dealt with appropriately, protecting public health and safety. In summary, the Therapeutic Goods Act 1989 provides clear provisions for the revocation of manufacturing licences for therapeutic goods, as evidenced by the recent notifications. These notifications detail specific obligations for the affected manufacturers and underscore the serious consequences of non-compliance, which can range from financial penalties to criminal charges. The Act’s provisions and penalties are designed to maintain high standards in the manufacture of therapeutic goods, ensuring they meet the necessary safety and quality requirements.